State Street® SPDR® S&P® Biotech ETF holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
State Street® SPDR® S&P® Biotech ETF XBI
Morningstar’s Analysis XBI
Will XBI outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 16.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Twist Bioscience Corp | 2.20 | 221M | Healthcare |
Moderna Inc | 2.04 | 206M | Healthcare |
Natera Inc | 1.81 | 183M | Healthcare |
United Therapeutics Corp | 1.65 | 167M | Healthcare |
Iovance Biotherapeutics Inc | 1.59 | 160M | Healthcare |
Biogen Inc | 1.55 | 156M | Healthcare |
Amgen Inc | 1.53 | 154M | Healthcare |
AbbVie Inc | 1.52 | 153M | Healthcare |
Spyre Therapeutics Inc | 1.52 | 153M | Healthcare |
CRISPR Therapeutics AG | 1.49 | 151M | Healthcare |